The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
Introduction Type 2 diabetes is a critical global health issue due to its rising prevalence and severe complications, including cardiovascular diseases, chronic kidney disease, and neuropathies, which reduce quality of life and increase mortality risk. While metformin remains a cornerstone of tre...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-01-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/57253 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576259226337280 |
|---|---|
| author | Jakub Waszczyński Wojciech Kulej Wiktor Biesiada Piotr Kulej Justyna Woźniak Justyna Weronika Kmieć Anna Mariia Chernysh Aleksandra Dusińska Kamila Fuczyło Karolina Stankević |
| author_facet | Jakub Waszczyński Wojciech Kulej Wiktor Biesiada Piotr Kulej Justyna Woźniak Justyna Weronika Kmieć Anna Mariia Chernysh Aleksandra Dusińska Kamila Fuczyło Karolina Stankević |
| author_sort | Jakub Waszczyński |
| collection | DOAJ |
| description |
Introduction
Type 2 diabetes is a critical global health issue due to its rising prevalence and severe complications, including cardiovascular diseases, chronic kidney disease, and neuropathies, which reduce quality of life and increase mortality risk. While metformin remains a cornerstone of treatment, incretin-based therapies like GLP-1 receptor agonists and DPP-4 inhibitors provide additional benefits, including glycemic control, weight management, and organ protection, making them essential in personalized care.
Aim of the Study
This study evaluates the mechanisms, efficacy, and benefits of GLP-1 receptor agonists and DPP-4 inhibitors in improving glycemic control, reducing cardiovascular risk, managing weight, and protecting renal function.
Materials and Methods
Data was sourced from recent clinical trials and literature (post-2020) from PubMed, Google Scholar, Lancet, New England Journal of Medicine, Nature, American Diabetes Association, Research Gate.
Results
GLP-1 receptor agonists demonstrated significant benefits, including a 27% reduction in major adverse cardiovascular events (MACE), a 32% decrease in kidney disease progression, and notable weight loss (e.g., 15.2% with semaglutide). These drugs also improved glycemic and metabolic parameters, though initial gastrointestinal side effects were common but temporary.
DPP-4 inhibitors showed nephroprotective effects, reducing albuminuria and slowing eGFR decline, and were associated with a lower hypoglycemia risk compared to sulfonylureas, particularly in advanced CKD. While less effective in weight management, they offered a weight-neutral option for patients with mild hyperglycemia or advanced CKD.
GLP-1 receptor agonists are ideal for high-risk or obese patients due to their strong glycemic and weight benefits, whereas DPP-4 inhibitors are safer for those with advanced CKD. |
| format | Article |
| id | doaj-art-05ac320036614f52bc8146e68423f0c0 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-05ac320036614f52bc8146e68423f0c02025-01-31T08:23:35ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-01-013710.12775/QS.2025.37.57253The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the LiteratureJakub Waszczyński0https://orcid.org/0009-0003-4156-2253Wojciech Kulejhttps://orcid.org/0009-0005-8059-1983Wiktor Biesiadahttps://orcid.org/0009-0002-2662-5300Piotr Kulejhttps://orcid.org/0009-0004-6655-6877Justyna Woźniakhttps://orcid.org/0009-0009-7785-4665Justyna Weronika Kmiećhttps://orcid.org/0009-0001-0570-9575Anna Mariia Chernyshhttps://orcid.org/0009-0008-6900-1593Aleksandra Dusińskahttps://orcid.org/0000-0001-5197-9683Kamila Fuczyłohttps://orcid.org/0000-0002-3443-8663Karolina Stankevićhttps://orcid.org/0009-0008-3572-1066PCK Marine Hospital in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia Introduction Type 2 diabetes is a critical global health issue due to its rising prevalence and severe complications, including cardiovascular diseases, chronic kidney disease, and neuropathies, which reduce quality of life and increase mortality risk. While metformin remains a cornerstone of treatment, incretin-based therapies like GLP-1 receptor agonists and DPP-4 inhibitors provide additional benefits, including glycemic control, weight management, and organ protection, making them essential in personalized care. Aim of the Study This study evaluates the mechanisms, efficacy, and benefits of GLP-1 receptor agonists and DPP-4 inhibitors in improving glycemic control, reducing cardiovascular risk, managing weight, and protecting renal function. Materials and Methods Data was sourced from recent clinical trials and literature (post-2020) from PubMed, Google Scholar, Lancet, New England Journal of Medicine, Nature, American Diabetes Association, Research Gate. Results GLP-1 receptor agonists demonstrated significant benefits, including a 27% reduction in major adverse cardiovascular events (MACE), a 32% decrease in kidney disease progression, and notable weight loss (e.g., 15.2% with semaglutide). These drugs also improved glycemic and metabolic parameters, though initial gastrointestinal side effects were common but temporary. DPP-4 inhibitors showed nephroprotective effects, reducing albuminuria and slowing eGFR decline, and were associated with a lower hypoglycemia risk compared to sulfonylureas, particularly in advanced CKD. While less effective in weight management, they offered a weight-neutral option for patients with mild hyperglycemia or advanced CKD. GLP-1 receptor agonists are ideal for high-risk or obese patients due to their strong glycemic and weight benefits, whereas DPP-4 inhibitors are safer for those with advanced CKD.https://apcz.umk.pl/QS/article/view/57253Type 2 Diabetes (T2D)GLP-1 receptor agonistsDPP-4 inhibitorsIncretin-Based TherapiesGlycemic ControlCardiovascular Risk |
| spellingShingle | Jakub Waszczyński Wojciech Kulej Wiktor Biesiada Piotr Kulej Justyna Woźniak Justyna Weronika Kmieć Anna Mariia Chernysh Aleksandra Dusińska Kamila Fuczyło Karolina Stankević The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature Quality in Sport Type 2 Diabetes (T2D) GLP-1 receptor agonists DPP-4 inhibitors Incretin-Based Therapies Glycemic Control Cardiovascular Risk |
| title | The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature |
| title_full | The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature |
| title_fullStr | The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature |
| title_full_unstemmed | The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature |
| title_short | The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature |
| title_sort | application of incretin based pharmacotherapy in the contemporary management of type 2 diabetes a review of the literature |
| topic | Type 2 Diabetes (T2D) GLP-1 receptor agonists DPP-4 inhibitors Incretin-Based Therapies Glycemic Control Cardiovascular Risk |
| url | https://apcz.umk.pl/QS/article/view/57253 |
| work_keys_str_mv | AT jakubwaszczynski theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT wojciechkulej theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT wiktorbiesiada theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT piotrkulej theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT justynawozniak theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT justynaweronikakmiec theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT annamariiachernysh theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT aleksandradusinska theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT kamilafuczyło theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT karolinastankevic theapplicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT jakubwaszczynski applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT wojciechkulej applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT wiktorbiesiada applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT piotrkulej applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT justynawozniak applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT justynaweronikakmiec applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT annamariiachernysh applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT aleksandradusinska applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT kamilafuczyło applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature AT karolinastankevic applicationofincretinbasedpharmacotherapyinthecontemporarymanagementoftype2diabetesareviewoftheliterature |